BMY-28864, a water-soluble pradimicin derivative, had potent in vitro activity against a wide variety of fungi, including those associated with deep-seated mycosis; it inhibited the growth of standard strains and clinical isolates at concentrations of 12.5 ,ug/ml or less. At the MIC or higher concentrations, BMY-28864 was fungicidal for Candida albicans under both growing and nongrowing conditions. BMY-28864 expressed fungicidal activity only in the presence of Ca2+, and its activity was totally diminished when ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), a Ca2+ chelator, was added to the test medium. The effectiveness of intravenously administered BMY-28864 in vivo was examined and compared with that of amphotericin B in mouse models of fungal infections. Both normal and cyclophosphamide-treated immunosuppressed mice infected with C. albicans, Cryptococcus neoformans, or Asperi'lus fumigatus responded to therapy with BMY-28864 (50% protective doses of 17, 18, and 37 mg/kg of body weight in normal mice and of 32, 35, and 51 mg/kg in cyclophosphamide-treated mice, respectively). Lethal lung infections were also established with C. albicans or A. fumigatus in cyclophosphamide-treated mice. The 50% protective doses of BMY-28864 were 15 and 23 mg/kg per dose against C. albicans and A. fumigatus, respectively. The immunosuppression induced by intraperitoneal administration of 200 mg of cyclophosphamide per kg lasted for 5 days, and total recovery was observed by day 7.
The rising incidence of systemic fungal infections in patients with suppressed immune systems brought about by the use of cytotoxic drugs, immunosuppressive therapy, or human immunodeficiency virus infection and the prolonged treatments that are necessary in these patients have highlighted the shortcomings of existing antifungal therapies. Amphotericin B remains the drug of choice for life-threatening fungal infections despite the relatively high degree of toxicity associated with its use, often a limiting factor in practice. Therefore, a need exists for fungicidal, broadspectrum, less-toxic antifungal agents to supplement the list of currently available antifungal drugs.
Pradimicin A is the original member of the pradimicins produced by Actinomadura hibisca P157-2 (ATCC 53557) (14, 15, 23, 24) . It possesses potent activity in vitro against a wide range of pathogenic fungi (16) and demonstrates in vivo efficacy against a large number of Candida albicans isolates (3) . Although pradimicin A is relatively nontoxic, its limited solubility in aqueous media at physiological pHs posed difficulties in further development. As part of the program aimed at identifying water-soluble derivatives, we embarked on microbial and chemical modification studies of pradimicin A (6, 7, 18, 20) and developed BMY-28864 (13) (Fig. 1) .
BMY-28864 was found to have broad and potent antifungal activity comparable to that of pradimicin A in vitro. It was water soluble (>40 mg/ml at pH 7.2) and well tolerated in mice; no acute lethal or apparent side effects were noted during 10 days of observation following an intravenous administration of up to 600 mg of BMY-28864 per kg of body weight. These properties would allow it to be readily formulated for intravenous administration. BMY-28864 was therefore examined in several fungal-infection models in mice * Corresponding author.
with normal immune and suppressed immune functions. In this report, we present the data on in vitro antifungal activity of BMY-28864 under a variety of conditions and compare the in vivo efficacy of BMY-28864 with that of amphotericin B against C. albicans, Cryptococcus neoformans, and Aspergillus fumigatus infections in normal and cyclophosphamide (CY)-treated immunosuppressed mice. Susceptibility testing. Broth dilution MICs were determined in 250-pul volumes in 96-well microtiter plates (Sumitomo Bakelite Co., Tokyo, Japan). Nine parts of yeast suspension (or spore suspension of A. fumigatus IAM 2034) were mixed with one part of antibiotic dilution. Inocula were adjusted to 105 cells per ml, except in experiments in which the effect of inoculum sizes was investigated. The plates were incubated at 37°C for 24 h without agitation, and the turbidity of individual wells was measured at 620 nm. MICs were defined as the lowest antibiotic concentrations that prevented visible growth, and 75% inhibitory concentrations were calculated from the turbidity readings of drug-treated cultures relative to those of untreated cultures that reached the stationary phase. The MIC results reported are those generated in at least two separate runs which agreed within a twofold range.
MATERIALS AND METHODS

Antibiotics
Agar dilution MICs were determined on phosphate-buffered YMA. Nine parts of molten agar were combined with one part of antibiotic dilution in petri dishes. A 5-,lI suspension containing 2 x 106 cells per ml (2 x 107 cells per ml for T. mentagrophytes 4329) was spotted on the surface of the agar plates. The plates were incubated at 28°C for 60 h. MICs were recorded after 40 h of incubation except for the T. mentagrophytes isolate, which required 60 h to produce visually evaluable growth on the drug-free control plates. Agar dilution MICs were defined as the lowest antibiotic concentrations showing no growth or less than five discrete colonies per spot.
Determination of fungicidal activity. Cells of C. albicans A9540 grown at 28°C for 5 h in YPG were collected by centrifugation. The effect of BMY-28864 on growing cells was studied by incubating cells (initial inoculum, 2 x 105 CFU/ml) in YNBG, pH 7.0, containing a fourfold series of antibiotic concentrations. Incubation of 20-ml volumes was at 28°C for 48 h in 100-ml Erlenmeyer flasks with shaking (100 rpm). Drug-free control cells grew only in the blastoconidial phase without forming any germ tubes or pseudohyphae under these conditions. Samples (1-ml aliquots) were removed at 1, 2, 4, 8,' 24, and 48 h, and the antibiotic was inactivated by diluting it 10-to 1,000 fold with 0.067 M phosphate buffer containing 2 mM EGTA (pH 7.2). The number of viable cells was determined from duplicate plate counts made on YPG-1.5% agar. The minimal accurately detectable number of viable cells was 5 x 10 CFU/ml.
The effect of BMY-28864 on nongrowing cells was studied by incubating cells (initial inoculum, 4 x 106 CFU/ml) in Dulbecco's PBS(+), pH 7.2, containing a fourfold series of antibiotic concentrations. Incubation of 20-ml volumes was at 28°C for 24 h in 100-ml Erlenmeyer flasks with shaking (100 rpm). Samples (1-ml aliquots) were removed at 1, 2, 4, 8, and 24 h, and the number of viable cells was determined by plating as described above for the experiment with growing cells.
Experimental infections in mice. Experimental systemic and lung infections were studied in specific-pathogen-free male ICR mice, each weighing 20 to 24 g. Neutropenia was induced by intraperitoneal administration of 200 mg of CY (Shionogi, Osaka, Japan) per kg 4 days before the fungal infection. This is a minor modification of the procedures described by others (1, 2, 5, 12) and produced a 70% albicans, the MICs of BMY-28864 increased (Table 2 ). This inoculum size effect was, however, much smaller than that observed for ketoconazole.
Effects of medium pH and serum. No variations in MICs of
BMY-28864 were noted as the medium pH varied from 5.0 to 8.5 in phosphate-buffered YMA (Table 3) . Similarly, addition of fetal bovine serum at concentrations of up to 50% did not affect the activity of BMY-28864 (Table 4 ). The activity of ketoconazole, on the other hand, was dependent on both the medium pH and the concentration of serum. Fungicidal activity. BMY-28864 was fungicidal to cells of C. albicans A9540 under both growing and nongrowing conditions. With an inoculum of 2 x iOs CFU/ml in YNBG, BMY-28864 at the MIC (6.3 ,ug/ml) or higher concentrations yielded a 3-log reduction in viable cells in 8 h or less (Fig. 2) . With an inoculum of 4 x 106 CFU/ml in PBS(+), BMY-28864 at 6.3 jxg/ml affected a 2-log reduction in viable cells in 24 h (Fig. 3) . strain each of S. cerevisiae (ATCC 9763), C. neoformans (IAM 4514), and A. fumigatus (IAM 2034) were tested in YNBG containing 2 mM EGTA, BMY-28864 at 100 pug/ml was. found to be ineffective in preventing organism growth. EGTA at concentrations of up to 2 mM did not affect the growth of these strains or alter their susceptibilities to amphotericin B (MICs ranged from 0.2 to 0.4 ,ug/ml). To further study the effect of Ca2+ on the activity of BMY-28864, the following experiment was carried out. Exposure of C. albicans A9540 (4 x 106 CFU/ml) to 25 jig of BMY-28864 per ml for 2 h at 28°C in PBS(+) resulted in a nearly 1-log reduction in viable cells, but the addition of EGTA at a final concentration of 2 mM and further incubation at 28°C for 22 h did not affect viability (Fig. 3) . As much as 7 ,ug of BMY-28864 per 4 x 106 CFU bound to C. albicans cells in PBS(+) but was recovered quantitatively when the antibiotic-bound cells were washed with 2 mM EGTA. Effect of BMY-28864 or amphotericin B on mouse survival during systemic infections. BMY-28864 and an'photericin B were comparatively evaluated in lethal systemic infections in normal and CY-treated immunosuppressed mice by a single intravenous administration. The results are summarized in Table 5 . By day 20, all untreated control mice died. BMY-28864 therapy at 25 or 50 mg/kg significantly prolonged the survival of C. albicans A9540-or C. neoformans IAM 4514-infected mice. The PD50s were 17 and 18 mg/kg in normal mice and 32 and 35 mg/kg in CY-treated mice, respectively. Against systemic aspergillosis, BMY-28864 therapy at 50 mg/kg resulted in the survival of 60 and 40% of normal and CY-treated mice, respectively. BMY-28864 ther- BMY-28864 was fungicidal to C. albicans under both growing and nongrowing conditions. It should be noted, however, that BMY-28864 expressed fungicidal activity only in the presence of Ca2+. The antifungal activity was totally diminished when EGTA, a Ca2+ chelator, was added to the test medium (Fig. 3) . As has been postulated for pradimicin A (21) and subsequently for BMY-28864 (19) , the mode of action of pradimicin is believed to begin with the strong Ca2'-dependent binding of the antibiotic to the cell wall mannan and mannoprotein. This is likely to result in changes in the three-dimensional arrangements of the cell wall polymers and in the contacts between cell wall and cell membrane, thus affecting, for example, natural cell wall autolysis with insertion of new cell wall materials and thereby causing alterations in membrane integrity. Although the precise mechanism of action of the pradimicin class of antifungal agents is not well understood, the fact that the fungicidal effect and mannan binding of the antibiotic were totally reversed with EGTA suggests that BMY-28864 is effective only when continuously bound to the cell wall components. BMY-28864 proved to be a well-tolerated drug in mice (13) and had no lytic effect on sheep erythrocytes in vitro. Our belief is that the selective toxicity of BMY-28864 to fungal VOL. 35, 1991 on December 29, 2017 by guest http://aac.asm.org/ Downloaded from cells is due to its specific binding to the fungal cell wall mannan and mannoprotein.
The present study demonstrated that the in vitro fungicidal activity of BMY-28864 was clearly translated into in vivo results. BMY-28864 given to normal mice by a single intravenous dosage was effective in systemic C. albicans, C. neoformans, and A. fumigatus infections, with PD50 values of 17, 18, and 37 mg/kg, respectively. BMY-28864 given by the same dosing schedule significantly prolonged the survival of CY-treated immunosuppressed mice infected systemically with C. albicans, C. neoformans, or A. fumigatus. Estimates of relative effectiveness and toxicity suggest that amphotericin B may be approximately 50-fold more effective and at least 130-fold more toxic than BMY-28864 on a milligram-per-kilogram level. In another experiment, a remarkable increase in the efficacy of BMY-28864 against systemic candidiasis was seen with a once-daily 5-day intravenous dosing schedule; the PD50 was 5.1 mg/kg per dose (data not shown).
Clearly, no experimental animal model completely simulates the complexities of individual neutropenic patients. Nevertheless, the lung models adopted in this study are considered to reflect a major route of lethal fungal infections in humans. Although the results are preliminary and detailed animal studies are needed, the effectiveness against C. albicans and A. fumigatus, good aqueous solubility [>40 mg/ml in PBS(+), pH 7.2], and low toxicity of BMY-28864 indicate the clinical potential of this compound for the prevention and treatment of opportunistic fungal infections in immunocompromised hosts.
